Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.16 (
HIV-1 protease
)
2,107
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Catalytic asymmetric synthesis of GRL-06579A (1), an
HIV-1 protease
inhibitor effective against multi-protease-inhibitor-resistant viruses, is described. A convergent strategy that utilizes heterobimetallic multifunctional catalysts developed in our group is a key feature of the synthesis. The chirality of the bicyclic tetrahydrofuran unit of 1 was introduced through Al-Li-bis(binaphthoxide) (ALB) catalyst-controlled Michael addition of dimethyl malonate to racemic 4-O-protected cyclopentenone. ALB afforded not only the trans adduct with up to 96% ee from a matched substrate through kinetic resolution, but also the cis adduct with 99% ee through a catalyst-controlled Michael addition to a mismatched substrate. The Michael addition to produce the unusual cis adduct is described in detail. The framework of the bicyclic tetrahydrofuran was constructed by an intramolecular oxy-Michael reaction. The amino alcohol unit was constructed by an La-Li3-tris(binaphthoxide) (LLB)-catalyzed diastereoselective nitroaldol reaction of N-Boc
aldehyde
(Boc = tert-butoxycarbonyl) derived from L-phenylalanine. LLB promoted the nitroaldol reaction without racemization of the chiral
aldehyde
to give the nitroaldol adduct in 85% yield and with 93:7 diastereoselectivity and over 99% ee.
...
PMID:Chiral-catalyst-based convergent synthesis of HIV protease inhibitor GRL-06579A. 1816 42
We describe an enantioselective synthesis of (3
R
,3
aS
,6
aR
)-hexahydrofuro[2,3-
b
]furan-3-ol which is a key subunit of darunavir, a widely used
HIV-1 protease
inhibitor drug for the treatment of HIV/AIDS patients. The synthesis was achieved in optically pure form utilizing commercially available sugar derivatives as the starting material. The key steps involve a highly stereoselective substrate-controlled hydrogenation, a Lewis acid catalyzed anomeric reduction of a 1,2-
O
-isopropylidene-protected glycofuranoside, and a Baeyer-Villiger oxidation of a tetrahydrofuranyl-2-
aldehyde
derivative. This optically active ligand alcohol was converted to darunavir efficiently.
...
PMID:The Chiron Approach to (3
R
,3
aS
,6
aR
)-Hexahydrofuro[2,3-
b
]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir. 3326 83